Cover
Vol. 13 No. 1 (2023)

Published: May 31, 2023

Pages: 1-20

Research Article

Correlation between Resistin and Follistatin hormones with pregnancy outcome in samples of Iraqi women undergoing ICSI cycle

Alyaa S. Mohammed 1 Wasan Al Jubori Saad Al-Dujaily
1High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq.
History
  • Received: April 7, 2023
  • Accepted: April 30, 2023
  • Available Online: May 8, 2023
DOI

https://doi.org/10.28969/IJEIR.v13.i1.r1.23

Abstract

Resistin and follistatin levels have been found to be high in polycystic ovarian syndrome (PCOS) patients, that play role in pathophysiology of PCOS and pregnancy status of women having ICSI cycle. This study aimed to determine the relationship between the hormone levels and pregnancy outcome in PCOS and non-PCOS women undergoing intracytoplasmic sperm injection (ICSI) program. The study was done at Higher Institute for Infertility Diagnosis and Assisted Reproductive Technologies from 2022 to 2023. Eighty infertile women participating in the IVF/ICSI treatment. They were split to control (40 non-polycystic ovarian syndrome-PCOS women) and 40 women for PCOS group. They were subdividing to subgroups’ according to body max index (BMI; normal and overweight / obese). ELISA method was used to measure hormone level at day 2 and follicular fluid and serum at day of ova pick up. About 38.8% of study participants were got pregnant. Means of serum resistin and follistatin in day 2 and OPU were significantly higher in patients with PCOS and normal BMI level while follistatin at day 2 and in follicular fluid (FF) were significantly higher in participants who got pregnant. Follistatin level at day 2 > 9.89 ng/ml and in FF > 15.06 ng/ml and might be as a predictor for occurrence of pregnancy after ICSI. The cutoff point of follistatin level in the serum at day two and in FF at the day OPU was found to be a predictor of pregnancy following ICSI, while no correlation was found between resistin and pregnancy outcome.

Keywords

References

  1. Jabeen A, Yamini V, Amberina AR, Eshwar MD, Vadakedath S, Begum GS. Polycystic Ovarian Syndrome: Prevalence, Predisposing Factors, and Awareness Among Adolescent and Young Girls of South India. Cureus. 2022;14 (8);1-14. https:// DOI 10.7759/cureus.27943
  2. Bulsara J, Patel P, Soni A, Acharya S. A review: Brief insight into Polycystic Ovarian syndrome. Endocrine and Metabolic Science. 2021;3:100085. https://doi.org/10.1016/j.endmts.2021.10008 5
  3. Liu Y, Zou G-J, Tu B-X, Hu Z-L, Luo C, Cui Y-H, et al. Corticosterone induced the increase of proBDNF in primary hippocampal neurons via endoplasmic reticulum stress. Neurotoxicity Research. 2020;38:370-84. https: //link. Springer .com /article /10.1007 /s12640-020-00201-4
  4. Raeisi T, Rezaie H, Darand M, Taheri A, Garousi N, Razi B, et al. Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis. PLoS One.2021;16 (3):e0246200. https://doi.org/10.1371/journal.pone.0246200
  5. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Met. 2013;98 (12):4565-92. https://doi.org/10.1210/jc.2013-2350
  6. Díaz M, de Zegher F, Ibáñez L. Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments. Frontiers in Endocrinology. 2023;14. https://doi.org/10.3389/fendo.2023.1125569
  7. Wu C, Borné Y, Gao R, López Rodriguez M, Roell WC, Wilson JM, et al. Elevated circulating follistatin is associates with an increased risk of type 2 diabetes. Nature Communications. 2021;12 (1):6486. https://doi.org/10.1038/s41467-021-26536-w
  8. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews. 2016;37 (5):467-520. https://doi.org/10.1210/er.2015- 1104
  9. Ramakrishnan KK, Sekar A, Subbiah M, Natarajan P. Comparison of transabdominal sonography and transvaginal sonography in the evaluation of endometrial thickness in the setting of abnormal uterine bleeding. Eastern J Medical Sciences. 2023;15-9 https://doi.org/10.32677/ejms.v8i1.3879
  10. World Health Organization, WHO laboratory manual for the examination and processing of human semen, 6th edition. 2021, Geneva: World Health Organization. doi: 10.5534/wjmh.210074
  11. Demirol A, Guven S. Agonists versus Antagonists in COH. Ovarian Stimulation Protocols. 2016;79-85. https://link.springer.com/chapter/10.1007/97 8-81-322-1121-1_5
  12. Bonduelle M, Camus M, De Vos A, Staessen C, Tournaye H, Van Assche E, et al. Seven years of intracytoplasmic sperm injection and follow-up of 1987 subsequent children. Human Reprodution. 1999;14 (suppl_1):243-64. https:// doi.org/10 .1093/ humrep /14.suppl _1.243
  13. Patrat C, Kaffel A, Delaroche L, Guibert J, Jouannet P, Epelboin S, et al. Optimal timing for oocyte denudation and intracytoplasmic sperm injection. Obst Gyn Internat. 2012;2012. https://doi.org/10.1155/2012/403531
  14. Malekkheili PG, Zadehmodarres S, Heidar Z. A comparative study of transabdominal and transvaginal ultrasound guidance on consequences of embryo transfer at Mahdiyeh Hospital of Tehran in 2020: An RCT. Intern J Reprod Bio Med. 2022;20 (3):169. https://doi: 10.18502/ijrm.v20i3.10708
  15. Patel L, Buckels A C, Kinghorn I J, Murdock PR, Holbrook J D, Plumpton C, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPARγ activators. Biochemical and biophysical research communications.2003; 300 (2): 472-476. https://doi.org/10.1016/S0006291X(02)0284 1-3
  16. Wakatsuki M A, Shintani Y A, Abe M, Liu Z H, Shitsukawa K E, Saito S H. Immunoradiometric assay for follistatin: serum immunoreactive follistatin levels in normal adults and pregnant women. The Journal of Clinical Endocrinology & Metabolism. 1996; 81 (2): 630-634. https://doi.org/10.1210/jcem.81.2.8636280
  17. Seow K-M, Juan C-C, Hsu Y-P, Ho L-T, Wang Y-Y, Hwang J-L. Serum and follicular resistin levels in women with polycystic ovarian syndrome during IVF-stimulated cycles. Hum Reprod. 2005;20 (1):117-21. https://doi.org/10.1093/humrep/deh589
  18. Wang J, Ding J, Qu B, Zhang Y, Zhou Q. Does Serum LH Level Influence IVF Outcomes in Women with PCOS Undergoing GnRH-Antagonist Stimulation: A Novel Indicator. J Clin Med. 2022;11 (16):4670- 4680. https://doi.org/10.3390/jcm11164670
  19. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisomeproliferator–activated receptor-γ action in humans. Diabetes. 2001;50 (10):2199-202. https://doi.org/10.2337/diabetes.50.10.2199
  20. Zhang J, Zhou L, Tang L, Xu L. The plasma level and gene expression of resistin in polycystic ovary syndrome. Gynecol Endocrinol. 2011;27 (12):982-7. https://doi.org/10.3109/09513590.2011.5697 94
  21. Baldani D P, Skrgatic L, Kasum M, Zlopasa G, Kralik Oguic S & Herman M. Altered leptin, adiponectin, resistin, and ghrelin secretion may represent an intrinsic polycystic ovary syndrome abnormality. Gynecological Endocrinology.2019; 35 (5): 401-405. https://doi.org/10.1080/09513590.2018.1534 096
  22. Steppan Cm and Lazar Ma. Resistin and obesity-associated insulin resistance. Trends in endocrino & metabolism .2002; 13 (1); pp.18-23. https://doi.org/10.1016/S10432760(01)00522 -7
  23. Norman Rj, Milner Cr, Groome Np, Robertson Dm. Circulating follistatin concentrations are higher, and activin concentrations are lower in polycystic ovarian syndrome. Human Reproduction .2001; 16 (4 ):pp.668–72. https: //doi.org/10. 1093/ humrep /16.4.668
  24. Pangaribuan B, Yusuf I, Mansyur M, Wijaya A . Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Therapeutic advances in endocrinol & metabolism .2011;2 (6): pp.235- 245. https://doi.org/10.1177/2042018811423770
  25. Al-Dujaily S, Abas R, Al-Musawi B, Al- Nakash A, Decleer W. Effect of activin A, follistatin and fibrillin-3 hormones on pregnancy rate in IVF programs. J Gynecol. 2016;1 (4):000121.
  26. Köninger A, Schmidt B, Damaske D, Birdir C, Enekwe A, Kimmig R., Gellhaus, A. Follistatin during pregnancy and its potential role as an ovarian suppressing agent. Eur J Obstet Gynecol Reprod Biol. 2017; 212:pp.150-154. https:// doi: 10.1016/j.ejogrb.2017.03.001
  27. Hamed E A, Sayyed H G, Abbas A M, Gaber M, Aleem H . Nesfatin-1, dopamine, and nadph levels in infertile women with polycystic ovary syndrome: is there a relationship between their levels and metabolic and hormonal variables. J Reprod Infertil .2022; 23:pp. 160-168. doi: 10.18502/jri.v23i3.10006 https://doi.org/10.3389/fendo.2021.788706